Ferring would like to use cookies to better understand your use of this website and improve your experience while navigating it. Please accept our use of cookies in accordance with our privacy policy

Accept / Decline

Press releases

Ferring appoints President of the Ferring Research Institute

Lausanne, Switzerland
April 2, 2004

Ferring, a biopharmaceutical company with its headquarters in Lausanne, Switzerland announced today that Dr. John L. McGuire has been appointed as the President of the Ferring Research Institute.

Dr. McGuire joins Ferring after 25 years with Johnson & Johnson. His most recent position was Corporate Vice President of Business Development in Johnson & Johnson's Pharmaceutical Group.

Dr. McGuire is an adjunct professor at the department of obstetrics, gynecology and reproductive sciences, University of Medicine and Dentistry of New Jersey, New Brunswick. He has published more than 200 scientific articles and edited several books.

Prior to his position as Corporate VP of Business Development, he held a variety of executive positions in R&D at Johnson & Johnson including Senior Vice President of Worldwide R&D at R.W. Johnson Pharmaceutical Research Institute. In addition to his R&D responsibilities, he was also responsible for identifying and in-licensing a number of important pharmaceutical products, notably erythropoietin.

Dr. McGuire has also held the position of Executive Director of Research at Ortho Pharmaceutical Corporation, a division of Johnson & Johnson. In this position he had responsibility for both drug discovery research as well as two independent clinical research and regulatory affairs units.

"We are delighted to welcome Dr. McGuire to the Ferring group" said Mr. Frederik Paulsen, Chairman of Ferring Group. "His experience and skills will ensure Ferring´s continued success in discovering interesting new compounds and bringing in new in-licensing opportunities, especially in the women's health care area." 

About Ferring:
Ferring is a Swiss based research driven, speciality biopharmaceutical group active in global markets.  The company identifies, develops and markets innovative products in the areas of urology, obstetrics and infertility, gastroenterology and endocrinology.

In recent years Ferring has expanded beyond its traditional European base and now has operating subsidiaries in over 40 countries.

Please visit us at www.Ferring.com

For more information, please contact:
Sharmi Albrechtsen
Ferring International Center
Telephone: + 45 28 78 72 09
Email: sharmi.albrechtsen@ferring.com 

See more Press releases



TEL:  +41 58 301 00 00
FAX: +41 58 301 00 10


Global Locator